



An Independent Licensee of the
Blue Cross and Blue Shield Association

Florida Blue
Quality Improvement and Care Management
DCC4-3
4800 Deerwood Campus Parkway
Jacksonville, FL 32246

<Date>

<Provider Name>
<Address>
<Address>
<City, State, Zip>

RE: Statin Therapy for Federal Employee Program[®] and Medicare Advantage Patients with Atherosclerotic Cardiovascular Disease and/or Diabetes

Dear <PCP or Prescriber Name>:

Florida Blue is committed to its Quality programs and improved health outcomes. Through claims information, we have identified Federal Employee Program and BlueMedicareSM Medicare Advantage members with **atherosclerotic cardiovascular disease (ASCVD)** and/or **diabetes** who have not filled their statin prescription(s) and/or do not have a suitable intensity statin therapy in 2018. We see this information as an important care opportunity and encourage you to work with your patients identified in the attached detailed report so they follow their appropriate statin therapy.

Guideline Information:

In 2014, the American College of Cardiology and American Heart Association revised treatment guidelines for cholesterol based on more recent evidence¹. Guidelines look at at-risk individuals and treatment based on statin intensity to reduce ASCVD. Four major statin benefit groups were identified for having the ASCVD risk reduction outweighing the risk of adverse events. As a result, two quality Healthcare Effectiveness Data and Information Set[®] (HEDIS) performance measures were added to national guidelines for two of the four statin benefit groups. This information is detailed in the tables below.

Statin Group 1: Patients with Clinical ASCVD		Statin Group 2: Patients with Diabetes	
<ul style="list-style-type: none"> Aged ≤75 years with clinical ASCVD should be started on a high-intensity statin; patients >75 years with clinical ASCVD or unable to tolerate high-intensity statin should receive a moderate-intensity statin. 		<ul style="list-style-type: none"> Aged 40-75 years and LDL-C 70 to 189 mg/dL without clinical ASCVD. 	
<ul style="list-style-type: none"> Treatment includes appropriate intensity statin in patients with clinical ASCVD was assigned a Grade A (strong) level of evidence supporting. 		<ul style="list-style-type: none"> Treatment: Moderate-intensity statin (Grade A level of evidence) and if the 10-year ASCVD risk is ≥7.5%; a high intensity statin should be considered (Grade B level of evidence). 	
	Quality Measure		
Description	Statin Use in Patient with Cardiovascular Disease (SPC)	Statin Use in Persons with Diabetes (SUPD)	
Population	Males 21-75 and females 40-75 years identified with clinical ASCVD through medical claims.	Patients 40-75 years with diabetes, identified through <u>two</u> prescription claims of hypoglycemic agents during 2018	
Measure Compliance	The measure is met when the patient has filled a prescription for a moderate to high intensity statin .	The measure is met when the patient has filled a prescription for a statin (any intensity).	
Weight	Star weight = 1	Star weight = 3	

The following table indicates the formulary status for moderate-intensity and high-intensity statins. Tier 6 Select Care drugs in the generic formulation have a \$0 copay² after any deductible is met.

Description	Prescription	
High-intensity Statin Therapy	Atorvastatin 40-80 mg (Tier 6)	Simvastatin 80 mg (Tier 6)
	Rosuvastatin 20-40 mg (Tier 6)	Amlodipine and Atorvastatin 40-80 mg (Tier 6)
	Ezetimibe and Atorvastatin 40-80 mg (non-formulary)	Ezetimibe and Simvastatin 80 mg (non-formulary)
Moderate-intensity Statin Therapy	Atorvastatin 10-20 mg (Tier 6)	Simvastatin 20-40 mg (Tier 6)
	lovastatin 40 mg (Tier 6)	Rosuvastatin 5-10 mg (Tier 6)
	Pravastatin 40-80 mg (Tier 6)	Amlodipine and Atorvastatin 10-20 mg (Tier 6)
	Ezetimibe and Simvastatin 20-40 mg (Tier 6)	Niacin and Lovastatin 40 mg (non-formulary)
	Sitagliptin – Simvastatin 20-40 mg (non-formulary)	Fluvastatin XL 80 mg (non-formulary)
	Ezetimibe and atorvastatin 10-20 mg (non-formulary)	Fluvastatin 40 mg bid (non-formulary)
	Niacin and Simvastatin 20-40 mg (non-formulary)	Pitavastatin 2-4 mg (non-formulary)

Please be sure to follow-up with your patient(s) regarding the clinical recommendations in this high-risk population.

Thank you for the care you provide to Florida Blue members. We appreciate being able to partner with you to help deliver the best care possible. We also welcome the occasion to discuss care opportunities with you. For questions or concerns related to BlueMedicare Medicare Advantage, please contact Dr. Kaplan 904-905-5551; Federal Employee Program, please contact Dr. Flaquer at 904-327-3718.

Sincerely,



Paul Kaplan, M.D.
Vice President
Quality Improvement, Medicare Stars
Florida Blue



Maria A. Flaquer, M.D.
Medical Director, Care Management
Federal Employee Program
Florida Blue

P.S. A HEDIS tip sheet explaining the Statin measure and others like it are available at floridablue.com located under the QUALITY/HEDIS/CAHPS and the Medicare Stars section found under Provider Tools & Resources (<https://www.floridablue.com/providers/tools-resources/Quality-Programs>).

¹Stone et al. 2014. 2013 ACC/AHA Blood Cholesterol Guideline. JACC 63(25):2889-934.

²Applies to BlueMedicare Medicare Advantage members.

Statin Use in Patient(s) with ASCVD and/or Diabetes

The following patient(s) was identified through claims as having ASCVD and/or diabetes; however, claims information indicates the patient(s) has **not filled a prescription and/or has not filled a prescription for an appropriate intensity statin this year**. We recognize claims information may be limited in describing each individual clinical scenario. Florida Blue's overall intent is to provide information to identify potentially actionable care opportunities, such as encouraging your patient(s) to be adherent with a medication you have already prescribed, adding or adjusting the statin medication, or reassessing statin medication/dose in patients with side effects.

If you would like to provide additional feedback regarding the member(s) listed below, please **fax your request to: 305-716-2714**.

Name	Member ID	Date of Birth	Statin Drug & Dose filled in 2018	Intensity	Measure Compliance Target
<LNAME>, <FNAME>	<MBRID>	<MBRDOB>	<DrugName/Dose>	<Intensity>	<Target >
Smith, Sally	h1234567	04/04/1944	lovastatin 20 mg	Low	Moderate-High Intensity
Doe, John	h1122334	05/05/1935	--none filled--	--	Any Intensity Statin